SCHEDULE: LCK JNK 1 LLC Discloses 6.33% Stake in Scinai Immunotherapeutics

LCK JNK 1 LLC has reported beneficial ownership of 317,366 American Depository Shares, representing 6.33% of Scinai Immunotherapeutics Ltd.'s outstanding shares, as of April 27, 2026.

Summary

• LCK JNK 1 LLC has filed a Schedule 13G, indicating it is a significant beneficial owner of Scinai Immunotherapeutics Ltd.
• The filing reports that LCK JNK 1 LLC beneficially owns 317,366 American Depository Shares (ADS) of Scinai Immunotherapeutics Ltd.
• This ownership stake represents 6.33% of the total class of securities.
• The date of the event requiring this filing was April 27, 2026.
• LCK JNK 1 LLC has sole voting power and sole dispositive power over these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership without additional commentary on the company's performance or future plans.

Positives

• LCK JNK 1 LLC has acquired a substantial stake (6.33%) in Scinai Immunotherapeutics Ltd., suggesting confidence in the company's future prospects.
• The reporting person has sole voting and dispositive power, indicating clear control over their investment.

Risks

• The filing does not explicitly detail any risks associated with the investment or the company's operations.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant shareholders to disclose their holdings in publicly traded companies. This filing indicates LCK JNK 1 LLC's substantial interest in Scinai Immunotherapeutics Ltd., which could signal potential future engagement or influence.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by LCK JNK 1 LLC may be of interest to other shareholders, potentially influencing market perception.
• Company Management: Scinai Immunotherapeutics Ltd. management will be aware of LCK JNK 1 LLC's substantial ownership, which could impact strategic discussions.

Next Steps

• LCK JNK 1 LLC will continue to hold its shares in Scinai Immunotherapeutics Ltd.
• Further filings may be required if LCK JNK 1 LLC's ownership stake changes significantly.

Key Dates

Keywords

Schedule 13G, Scinai Immunotherapeutics Ltd., LCK JNK 1 LLC, Beneficial Ownership, American Depository Shares, SEC Filing, Investment, Shareholder